After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
A 12-foot great white shark, tracked from Nova Scotia, has been detected in the Mississippi Sound, marking an unusual westward migration into the Gulf and offering clues about the region's marine health.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
With consumer staples out of favor and a yield surpassing the S&P 500, Coca-Cola's resilient business and decades of dividend growth present a compelling case for long-term investors.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Despite a new U.S. framework for involvement, extracting Greenland's rare earth metals is hampered by Arctic extremes, local political opposition, and strained transatlantic ties.
Despite a challenging housing market, Five Point Holdings (NYSE:FPH) reported record annual net income for 2025, driven by strategic land sales and the integration of its Hearthstone platform. The company navigated economic uncertainty with disciplined pricing and secured major entitlement approvals to fuel its long-term pipeline.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Analyst sell ratings are rare on Wall Street, making them noteworthy when they appear. We examine one such case where pessimism may have gone too far, creating a potential opportunity, alongside two stocks where the cautious outlook appears justified.
Charter Communications shares surged Friday after the cable giant reported a rare quarterly gain in pay-TV subscribers, a bright spot amid ongoing broadband pressures. The company's strategy of bundling streaming services appears to be resonating with customers.
Damascus residents face electricity bills exceeding their monthly incomes after a massive government price hike, sparking rare public protests and deepening the crisis for a war-weary population.
From economic despair to demands for fundamental rights, Iran's recent wave of protests revealed a rare, broad-based defiance. Through the eyes of those who were there, a story emerges of fleeting hope shattered by a security response activists call the deadliest in decades.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
SpaceX is reportedly targeting June 2026 for its long-awaited public market debut, with sources suggesting the timing could be synchronized with a rare planetary alignment and CEO Elon Musk's 55th birthday, as the company seeks capital for its ambitious Mars missions.
In a rare show of unity, Pennsylvania's political leaders from both parties are rallying behind the state's famed weather-predicting groundhog, pushing back against an animal rights group's call to replace the living animal with a digital projection.
The enterprise software firm's unprecedented Bitcoin treasury position fell below its average cost basis over the weekend, marking a rare paper loss event, even as the company continues its aggressive acquisition strategy.
A damning report from the EU's financial watchdog reveals the bloc's struggle to secure the minerals essential for its climate goals, highlighting failed trade deals, stalled recycling, and persistent over-reliance on external suppliers.
A damning report from the European Court of Auditors reveals the bloc is falling dangerously behind in securing the lithium, cobalt, and nickel needed for its energy transition, leaving climate goals and strategic autonomy in jeopardy.
